Nexien BioPharma, Inc.
NXEN · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | 0.13 | 0.09 | 0.08 |
| FCF Yield | -5.52% | -3.67% | -2.08% | -1.82% |
| EV / EBITDA | -9.44 | -8.71 | -8.20 | -2.70 |
| Quality | ||||
| ROIC | 318.40% | -1,451.34% | -326.95% | 89,940.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.27 | 0.23 | 0.12 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 21.27% | -8.79% | 17.19% | 38.51% |
| Safety | ||||
| Net Debt / EBITDA | -1.97 | -0.84 | -0.23 | 0.00 |
| Interest Coverage | -1.87 | -3.57 | -5.46 | -46.37 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |